Systematic analysis of transcription-level effects of neurodegenerative diseases on human brain metabolism by a newly reconstructed brain-specific metabolic network

FEBS Open Bio

Volumn 4, Issue , 2014, Pages 542-553

  Sertbaş, Mustafa ^a,b   Ülgen, Kutlu ^b   Çakir, Tunahan ^a  

^a GEBZE TECHNICAL UNIVERSITY   (Turkey)

^b BOGAZICI UNIVERSITY   (Turkey)

Author keywords

Brain metabolic network; Computational systems biology; Neurodegenerative diseases; Neurometabolism; Reporter metabolite; Transcriptome

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATE; ALANINE; ASPARTIC ACID; CREATINE; GLUTAMIC ACID; GUANOSINE TRIPHOSPHATE; HOMOCYSTEINE; ISOLEUCINE; KETONE BODY; METHIONINE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SPHINGOMYELIN; TRANSCRIPTION FACTOR; UPSTREAM STIMULATORY FACTOR 1; ASPARAGINE; INOSITOL; LEUCINE; PURINE NUCLEOSIDE; PYRIMIDINE NUCLEOSIDE; TRANSCRIPTOME; VALINE;

AEROBIC METABOLISM; ALZHEIMER DISEASE; AMINO ACID METABOLISM; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ASTROCYTE; BINDING SITE; BRAIN METABOLISM; CEREBROSPINAL FLUID; CHOLESTEROL METABOLISM; CITRIC ACID CYCLE; DEGENERATIVE DISEASE; DISEASE MARKER; ENERGY METABOLISM; HUMAN; HUNTINGTON CHOREA; ILLUMINATION; LIPID METABOLISM; LIPOGENESIS; MULTIPLE SCLEROSIS; NERVE CELL; NERVOUS SYSTEM; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; SCHIZOPHRENIA; SYSTEMS BIOLOGY; DISEASES; MACHINE; METABOLISM; OXIDATIVE PHOSPHORYLATION; PENTOSE PHOSPHATE CYCLE; SYSTEMATIC REVIEW;

EID: 84902974185     PISSN: 22115463     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fob.2014.05.006     Document Type: Article

References (143)

1. Forman M.S., Trojanowski J.Q., Lee V.M. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat. Med. 2004, 10:1055-1063.
2. Wancata J., Musalek M., Alexandrowicz R., Krautgartner M. Number of dementia sufferers in Europe between the years 2000 and 2050. Eur. Psychiatry 2003, 18(6):306-313.
3. Bach J.-P., Ziegler U., Deuschl G., Dodel R., Doblhammer-Reiter G. Projected numbers of people with movement disorders in the years 2030 and 2050. Mov. Disord. 2011, 26:2286-2290.
4. Prabakaran S., Swatton J.E., Ryan M.M., Huffaker S.J., Huang J.T.-J., Griffin J.L., Wayland M., Freeman T., Dudbridge F., Lilley K.S. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol. Psychiatry 2004, 9:684-697.
5. Brooks W.M., Lynch P.J., Ingle C.C., Hatton A., Emson P.C., Faull R.L.M., Starkey M.P. Gene expression profiles of metabolic enzyme transcripts in Alzheimer's disease. Brain Res. 2007, 1127:127-135.
6. Çakir T., Alsan S., Saybaşili H., Akin A., Ülgen K.Ö. Reconstruction and flux analysis of coupling between metabolic pathways of astrocytes and neurons: application to cerebral hypoxia. Theor. Biol. Med. Model. 2007, 4:48.
7. Lewis N.E., Schramm G., Bordbar A., Schellenberger J., Andersen M.P., Cheng J.K., Patel N., Yee A., Lewis R.A., Eils R. Large-scale in silico modeling of metabolic interactions between cell types in the human brain. Nat. Biotechnol. 2010, 28:1279-1285.
8. Occhipinti R., Puchowicz M.A., LaManna J.C., Somersalo E., Calvetti D. Statistical analysis of metabolic pathways of brain metabolism at steady state. Ann. Biomed. Eng. 2007, 35:886-902.
9. Gille C., Bölling C., Hoppe A., Bulik S., Hoffmann S., Hübner K., Karlstädt A., Ganeshan R., König M., Rother K. HepatoNet1: a comprehensive metabolic reconstruction of the human hepatocyte for the analysis of liver physiology. Mol. Syst. Biol. 2010, 6(411). 10.1038/msb.2010.62.
10. Zelezniak A., Pers T.H., Soares S., Patti M.E., Patil K.R. Metabolic network topology reveals transcriptional regulatory signatures of type 2 diabetes. PLoS Comput. Biol. 2010, 6:e1000729. 10.1371/journal.pcbi.1000729.
11. Romero P., Wagg J., Green M.L., Kaiser D., Krummenacker M., Karp P.D. Computational prediction of human metabolic pathways from the complete human genome. Genome Biol. 2004, 6:2.
12. Kauffman K.J., Prakash P., Edwards J.S. Advances in flux balance analysis. Curr. Opin. Biotechnol. 2003, 14(5):491-496.
13. Mahadevan R., Schilling C.H. The effects of alternate optimal solutions in constraint-based genome-scale metabolic models. Metab. Eng. 2003, 5:264-276.
14. Shen J., Petersen K.F., Behar K.L., Brown P., Nixon T.W., Mason G.F., Petroff O.A., Shulman G.I., Shulman R.G., Rothman D.L. Determination of the rate of the glutamate/glutamine cycle in the human brain by in vivo 13C NMR. Proc. Natl. Acad. Sci. U.S.A. 1999, 96(14):8235-8240.
15. Gruetter R. In vivo 13C NMR studies of compartmentalized cerebral carbohydrate metabolism. Neurochem. Int. 2002, 41(2-3):143-154.
16. Holzhütter H.-G. The principle of flux minimization and its application to estimate stationary fluxes in metabolic networks. Eur. J. Biochem. 2004, 271(14):2905-2922. 10.1111/j.1432-1033.2004.04213.x.
17. Bonarius H.P., Hatzimanikatis V., Meesters K.P., de Gooijer C.D., Schmid G., Tramper J. Metabolic flux analysis of hybridoma cells in different culture media using mass balances. Biotechnol. Bioeng. 1996, 50(3):299-318.
18. Durrenberger P.F., Fernando F.S., Magliozzi R., Kashefi S.N., Bonnert T.P., Ferrer I., Seilhean D., Nait-Oumesmar B., Schmitt A., Gebicke-Haerter P.J., Falkai P., Grünblatt E., Palkovits M., Parchi P., Capellari S., Arzberger T., Kretzschmar H., Roncaroli F., Dexter D.T., Reynolds R. Selection of novel reference genes for use in the human central nervous system: a BrainNet Europe Study. Acta Neuropathol. 2012, 124(6):893-903.
19. Schapira A.H.V., Cooper J.M., Dexter D., Clark J.B., Jenner P., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 1990, 54(3):823-827.
20. Janetzky B., Hauck S., Youdim M.B.H., Riederer P., Jellinger K., Pantucek F., Zöchling R., Boissl K.W., Reichmann H. Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci. Lett. 1994, 169:126-128.
21. Tretter L., Sipos I., Adam-Vizi V. Initiation of neuronal damage by complex I deficiency and oxidative stress in Parkinson's disease. Neurochem. Res. 2004, 29:569-577.
22. Dutta R., McDonough J., Yin X., Peterson J., Chang A., Torres T., Gudz T., Macklin W.B., Lewis D.A., Fox R.J., Rudick R., Mirnics K., Trapp B.D. Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann. Neurol. 2006, 59(3):478-489.
23. Forster D.M., James M.F., Williams S.R. Effects of Alzheimer's disease transgenes on neurochemical expression in the mouse brain determined by 1H MRS in vitro. NMR Biomed. 2012, 25:52-58.
24. Mizuno Y., Matuda S., Yoshino H., Mori H., Hattori N., Ikebe S.-I. An immunohistochemical study on α-ketoglutarate dehydrogenase complex in Parkinson's disease. Ann. Neurol. 1994, 35:204-210.
25. Gibson G.E., Kingsbury A.E., Xu H., Lindsay J.G., Daniel S., Foster O.J.F., Lees A.J., Blass J.P. Deficits in a tricarboxylic acid cycle enzyme in brains from patients with Parkinson's disease. Neurochem. Int. 2003, 43:129-135.
26. Gibson G.E., Sheu K.-F.R., Blass J.P. Abnormalities of mitochondrial enzymes in Alzheimer disease. J. Neural Transm. 1998, 105:855-870.
27. Bubber P., Haroutunian V., Fisch G., Blass J.P., Gibson G.E. Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann. Neurol. 2005, 57:695-703.
28. Gibson G.E., Blass J.P., Beal M.F., Bunik V. The α-ketoglutarate-dehydrogenase complex. Mol. Neurobiol. 2005, 31:43-63.
29. Martins-de-Souza D., Gattaz W.F., Schmitt A., Novello J.C., Marangoni S., Turck C.W., Dias-Neto E. Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation. BMC Psychiatry 2009, 9:17. 10.1186/1471-244X-9-17.
30. Bubber P., Hartounian V., Gibson G.E., Blass J.P. Abnormalities in the tricarboxylic acid (TCA) cycle in the brains of schizophrenia patients. Eur. Neuropsychopharmacol. 2011, 21:254-260.
31. Browne S.E., Ferrante R.J., Beal M.F. Oxidative stress in Huntington's disease. Brain Pathol. 1999, 9:147-163.
32. 1H NMR spectroscopy. Neurology 1993, 43:2689.
33. Koroshetz W.J., Jenkins B.G., Rosen B.R., Beal M.F. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann. Neurol. 1997, 41:160-165.
34. Wen J.H., Chen Y.Y., Song S.J., Ding J., Gao Y., Hu Q.K., Feng R.P., Liu Y.Z., Ren G.C., Zhang C.Y. Paired box 6 (PAX6) regulates glucose metabolism via proinsulin processing mediated by prohormone convertase 1/3 (PC1/3). Diabetologia 2009, 52:504-513.
35. Thompson J.A., Ziman M. Pax genes during neural development and their potential role in neuroregeneration. Prog. Neurobiol. 2011, 95(3):334-351.
36. Schulz J.B., Lindenau J., Seyfried J., Dichgans J. Glutathione, oxidative stress and neurodegeneration. Eur. J. Biochem. 2000, 267(16):4904-4911. 10.1046/j.1432-1327.2000.01595.x.
37. Barnham K.J., Masters C.L., Bush A.I. Neurodegenerative diseases and oxidative stress. Nat. Rev. Drug Discov. 2004, 3:205-214.
38. Chong Z.Z., Li F., Maiese K. Oxidative stress in the brain: novel cellular targets that govern survival during neurodegenerative disease. Prog. Neurobiol. 2005, 75(3):207-246.
39. Essers M.A., Weijzen S., de Vries-Smits A.M., Saarloos I., de Ruiter N.D., Bos J.L., Burgering B.M. FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK. EMBO J. 2004, 23:4802-4812.
40. Desplats P., Patel P., Kosberg K., Mante M., Patrick C., Rockenstein E., Fujita M., Hashimoto M., Masliah E. Combined exposure to Maneb and Paraquat alters transcriptional regulation of neurogenesis-related genes in mice models of Parkinson's disease. Mol. Neurodegener. 2012, 7:49. 10.1186/1750-1326-7-49.
41. Mairet-Coello G., Tury A., Fellmann D., Jouvenot M., Griffond B. Expression of SOx-2, a member of the FAD-dependent sulfhydryl oxidase/quiescin Q6 gene family, in rat brain. NeuroReport 2002, 13:2049-2051.
42. Ferri A.L., Cavallaro M., Braida D., Di Cristofano A., Canta A., Vezzani A., Ottolenghi S., Pandolfi P.P., Sala M., DeBiasi S. Sox2 deficiency causes neurodegeneration and impaired neurogenesis in the adult mouse brain. Development 2004, 131:3805-3819.
43. Chen J., Wang X., Yi X., Wang Y., Liu Q., Ge R. Induction of KLF4 contributes to the neurotoxicity of MPP+ in M17 cells: a new implication in Parkinson's disease. J. Mol. Neurosci. 2013, 1-9.
44. Stockler S., Schutz P.W., Salomons G.S. Cerebral creatine deficiency syndromes: clinical aspects, treatment and pathophysiology. Creatine and Creatine Kinase in Health and Disease 2008, 149-166. Springer. 10.1007/978-1-4020-6486-9_8.
45. David S., Shoemaker M., Haley B.E. Abnormal properties of creatine kinase in Alzheimer's disease brain: correlation of reduced enzyme activity and active site photolabeling with aberrant cytosol-membrane partitioning. Mol. Brain Res. 1998, 54:276-287.
46. Wendt S., Dedeoglu A., Speer O., Wallimann T., Beal M.F., Andreassen O.A. Reduced creatine kinase activity in transgenic amyotrophic lateral sclerosis mice. Free. Radic. Biol. Med. 2002, 32:920-926.
47. Öngür D., Prescot A.P., Jensen J.E., Cohen B.M., Renshaw P.F. Creatine abnormalities in schizophrenia and bipolar disorder. Psychiatry Res. Neuroimaging 2009, 172:44-48.
48. Burbaeva G.S., Savushkina O.K., Boksha I.S. Creatine kinase BB in brain in schizophrenia. World J. Biol. Psychiatry 2003, 4:177-183.
49. Adhihetty P.J., Beal M.F. Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases. Neuromolecular Med. 2008, 10:275-290.
50. Tarnopolsky M.A., Beal M.F. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann. Neurol. 2001, 49:561-574.
51. Klein M., Ferrante R.J. The neuroprotective role of creatine. Creatine and Creatine Kinase in Health and Disease 2008, 205-243. Springer, .
52. Kashiwaya Y., Takeshima T., Mori N., Nakashima K., Clarke K., Veech R.L. D-β-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease. Proc. Natl. Acad. Sci. 2000, 97:5440-5444.
53. Müller T., Woitalla D., Hauptmann B., Fowler B., Kuhn W. Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease. Neurosci. Lett. 2001, 308(1):54-56.
54. Mally J., Szalai G., Stone T.W. Changes in the concentration of amino acids in serum and cerebrospinal fluid of patients with Parkinson's disease. J. Neurol. Sci. 1997, 151:159-162.
55. Antonio Molina J., Javier Jiménez-Jiménez F., Gómez P., Vargas C., AntonioNavarro J., Ortí-Pareja M., Gasalla T., BenitoLeón J., Bermejo F., Arenas J. Decreased cerebrospinal fluid levels of neutral and basic amino acids in patients with Parkinson's disease. J. Neurol. Sci. 1997, 150:123-127.
56. Reilmann R., Rolf L.H., Lange H.W. Decreased plasma alanine and isoleucine in Huntington's disease. Acta Neurol. Scand. 1995, 91(3):222-224.
57. Kim J.S., Kornhuber H.H., Holzmüller B., Schmid-Burgk W., Mergner T., Krzepinski G. Reduction of cerebrospinal fluid glutamic acid in Huntington's chorea and in schizophrenic patients. Arch. Psychiatr. Nervenkr. 1980, 228:7-10.
58. Monaco F., Fumero S., Mondino A., Mutani R. Plasma and cerebrospinal fluid tryptophan in multiple sclerosis and degenerative diseases. J. Neurol. Neurosurg. Psychiatry 1979, 42:640-641.
59. Bjerkenstedt L., Edman G., Hagenfeldt L., Sedvall G., Wiesel F.A. Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls. Br. J. Psychiatry 1985, 147:276-282.
60. Piccinini M., Scandroglio F., Prioni S., Buccinnà B., Loberto N., Aureli M., Chigorno V., Lupino E., DeMarco G., Lomartire A. Deregulated sphingolipid metabolism and membrane organization in neurodegenerative disorders. Mol. Neurobiol. 2010, 41:314-340.
61. Hanley M.R., Jackson T.R., Vallejo M., Patterson S.I., Thastrup O., Lightman S., Rogers J., Henderson G., Pini A., Downes C.P. Neural function: metabolism and actions of inositol metabolites in mammalian brain [and discussion]. Philos. Trans. R. Soc. London. B, Biol. Sci. 1988, 320:381-398.
62. Brady S.T., Siegel G.J., Albers R.W., Price D.L. Basic Neurochemistry: Principles of Molecular, Cellular and Medical Neurobiology 2012, Elsevier Academic Press.
63. Stokes C.E., Hawthorne J.N. Reduced phosphoinositide concentrations in anterior temporal cortex of Alzheimer-diseased brains. J. Neurochem. 1987, 48:1018-1021.
64. Miller B.L., Moats R.A., Shonk T., Ernst T., Woolley S., Ross B.D. Alzheimer disease: depiction of increased cerebral myo-inositol with proton MR spectroscopy. Radiology 1993, 187:433-437.
65. Kalra S., Hanstock C.C., Martin W.R., Allen P.S., Johnston W.S. Detection of cerebral degeneration in amyotrophic lateral sclerosis using high-field magnetic resonance spectroscopy. Arch. Neurol. 2006, 63:1144-1148. 10.1001/archneur.63.8.1144.
66. Teunissen C.E., Dijkstra C.D., Polman C.H., Hoogervorst E.L.J., von Bergmann K., Lütjohann D. Decreased levels of the brain specific 24S-hydroxycholesterol and cholesterol precursors in serum of multiple sclerosis patients. Neurosci. Lett. Aug. 2003, 347(3):159-162.
67. van de Kraats C., Killestein J., Popescu V., Rijkers E., Vrenken H., Lutjohann D., Barkhof F., Polman C., Teunissen C. Oxysterols and cholesterol precursors correlate to magnetic resonance imaging measures of neurodegeneration in multiple sclerosis. Mult. Scler. J. 2014, 20:412-417. 10.1177/1352458513499421.
68. Isotalo K., Kok E.H., Luoto T.M., Haikonen S., Haapasalo H., Lehtimäki T., Karhunen P.J. Upstream transcription factor 1 (USF1) polymorphisms associate with Alzheimer's disease-related neuropathological lesions: Tampere Autopsy Study. Brain Pathol. 2012, 22(6):765-775.
69. Pfrieger F.W. Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes?. Bioessays 2003, 25(1):72-78. 10.1002/bies.10195.
70. Sanchez H.B., Yieh L., Osborne T.F. Cooperation by sterol regulatory element-binding protein and Sp1 in sterol regulation of low density lipoprotein receptor gene. J. Biol. Chem. 1995, 270:1161-1169.
71. Dunah A.W., Jeong H., Griffin A., Kim Y.-M., Standaert D.G., Hersch S.M., Mouradian M.M., Young A.B., Tanese N., Krainc D. Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 2002, 296:2238-2243.
72. Qiu Z., Norflus F., Singh B., Swindell M.K., Buzescu R., Bejarano M., Chopra R., Zucker B., Benn C.L., DiRocco D.P. Sp1 is up-regulated in cellular and transgenic models of Huntington disease, and its reduction is neuroprotective. J. Biol. Chem. 2006, 281:16672-16680.
73. Citron B.A., Dennis J.S., Zeitlin R.S., Echeverria V. Transcription factor Sp1 dysregulation in Alzheimer's disease. J. Neurosci. Res. 2008, 86(11):2499-2504.
74. Santpere G., Nieto M., Puig B., Ferrer I. Abnormal Sp1 transcription factor expression in Alzheimer disease and tauopathies. Neurosci. Lett. 2006, 397(1-2):30-34.
75. Kristjansdottir G., Sandling J.K., Bonetti A., Roos I.M., Milani L., Wang C., Gustafsdottir S.M., Sigurdsson S., Lundmark A., Tienari P.J. Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations. J. Med. Genet. 2008, 45:362-369.
76. Gobin S.J.P., Montagne L., Zutphen M.V., Valk P.V.D., Elsen P.J.V.D., Groot C.J.A.D. Upregulation of transcription factors controlling MHC expression in multiple sclerosis lesions. Glia 2001, 36(1):68-77.
77. Sammon J.W. A nonlinear mapping for data structure analysis. Comput. IEEE Trans. 1969, 100:401-409.
78. Wit E., McClure J. Statistics for Microarrays: Design, Analysis and Inference 2004, John Wiley & Sons.
79. Durany N., Joseph J., Cruz-SÃ F.F., Carreras J. Phosphoglycerate mutase, 2, 3-bisphosphoglycerate phosphatase and creatine kinase activity and isoenzymes in human brain tumours. Br. J. Cancer 1997, 76:1139-1149.
80. Burbaeva G.S., Turishcheva M.S., Vorobyeva E.A., Savushkina O.K., Tereshkina E.B., Boksha I.S. Diversity of glutamate dehydrogenase in human brain. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26(3):427-435. 10.1016/S0278-5846(01)00273-1.
81. Schmoll D., Führmann E., Gebhardt R., Hamprecht B. Significant amounts of glycogen are synthesized from 3-carbon compounds in astroglial primary cultures from mice with participation of the mitochondrial phosphoenolpyruvate carboxykinase isoenzyme. Eur. J. Biochem. 1995, 227(1-2):308-315.
82. Cruz F., Scott S.R., Barroso I., Santisteban P., Cerdán S. Ontogeny and cellular localization of the pyruvate recycling system in rat brain. J. Neurochem. 1998, 70(6):2613-2619.
83. Beigneux A.P., Kosinski C., Gavino B., Horton J.D., Skarnes W.C., Young S.G. ATP-citrate lyase deficiency in the mouse. J. Biol. Chem. 2004, 279:9557-9564.
84. Cahoy J.D., Emery B., Kaushal A., Foo L.C., Zamanian J.L., Christopherson K.S., Xing Y., Lubischer J.L., Krieg P.A., Krupenko S.A. A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J. Neurosci. 2008, 28:264-278.
85. Smith Q.R. Transport of glutamate and other amino acids at the blood-brain barrier. J. Nutr. 2000, 130(4):1016S-1022S.
86. Krusong K., Ercan-Sencicek A.G., Xu M., Ohtsu H., Anderson G.M., State M.W., Pittenger C. High levels of histidine decarboxylase in the striatum of mice and rats. Neurosci. Lett. 2011, 495(2):110-114.
87. Brown R.E., Stevens D.R., Haas H.L. The physiology of brain histamine. Prog. Neurobiol. 2001, 63(6):637-672.
88. Nishibori M., Tahara A., Sawada K., Sakiyama J., Nakaya N., Saeki K. Neuronal and vascular localization of histamine N-methyltransferase in the bovine central nervous system. Eur. J. Neurosci. 2000, 12(2):415-424.
89. McBean G.J. The transsulfuration pathway: a source of cysteine for glutathione in astrocytes. Amino Acids 2012, 42:199-205.
90. Vitvitsky V., Thomas M., Ghorpade A., Gendelman H.E., Banerjee R. A functional transsulfuration pathway in the brain links to glutathione homeostasis. J. Biol. Chem. 2006, 281:35785-35793.
91. Spector R., Coakley G., Blakely R. Methionine recycling in brain: a role for folates and vitamin B-12. J. Neurochem. 1980, 34(1):132-137.
92. Lajtha A., Oja S.S., Schousboe A., Saransaari P. Handbook of Neurochemistry and Molecular Neurobiology: Amino Acids and Peptides in the Nervous System 2007, Springer.
93. Wiesinger H. Glia-specific enzyme systems. Neuroglia 1995, 488-499. Oxford University Press, New York.
94. Regunathan S., Feinstein D.L., Raasch W., Reis D.J. Agmatine (decarboxylated arginine) is synthesized and stored in astrocytes. NeuroReport 1995, 6:1897-1900.
95. Braissant O., Gotoh T., Loup M., Mori M., Bachmann C. L-arginine uptake, the citrulline-NO cycle and arginase II in the rat brain: an in situ hybridization study. Mol. Brain Res. Jul. 1999, 70:231-241.
96. Iyo A.H., Zhu M.-Y., Ordway G.A., Regunathan S. Expression of arginine decarboxylase in brain regions and neuronal cells. J. Neurochem. 2006, 96(4):1042-1050.
97. Wiesinger H. Arginine metabolism and the synthesis of nitric oxide in the nervous system. Prog. Neurobiol. 2001, 64(4):365-391.
98. Nakamura H., Itoh K., Kawabuchi M. NADPH-diaphorase and cytosolic urea cycle enzymes in the rat accessory olfactory bulb. J. Chem. Neuroanat. 1999, 17:109-117.
99. Arnt-Ramos L.R., O'Brien W.E., Vincent S.R. Immunohistochemical localization of argininosuccinate synthetase in the rat brain in relation to nitric oxide synthase-containing neurons. Neuroscience 1992, 51:773-789.
100. Shank R.P., Campbell G.LeM. Ornithine as a precursor of glutamate and GABA: uptake and metabolism by neuronal and glial enriched cellular material. J. Neurosci. Res. 1983, 9:47-57.
101. Ma K., Deutsch J., Villacreses N.E., Rosenberger T.A., Rapoport S.I., Shetty H.U. Measuring brain uptake and incorporation into brain phosphatidylinositol of plasma myo-[2H6] inositol in unanesthetized rats: an approach to estimate in vivo brain phosphatidylinositol turnover. Neurochem. Res. 2006, 31:759-765.
102. Inhorn R.C., Bansal V.S., Majerus P.W. Pathway for inositol 1, 3, 4-trisphosphate and 1, 4-bisphosphate metabolism. Proc. Natl. Acad. Sci. U.S.A 1987, 84:2170-2174.
103. Fisher S.K., Novak J.E., Agranoff B.W. Inositol and higher inositol phosphates in neural tissues: homeostasis, metabolism and functional significance. J. Neurochem. 2002, 82(4):736-754.
104. Braissant O., Henry H., Loup M., Eilers B., Bachmann C. Endogenous synthesis and transport of creatine in the rat brain: an in situ hybridization study. Mol. Brain Res. 2001, 86(1-2):193-201.
105. Molloy G.R., Wilson C.D., Benfield P., de Vellis J., Kumar S. Rat brain creatine kinase messenger RNA levels are high in primary cultures of brain astrocytes and oligodendrocytes and low in neurons. J. Neurochem. 1992, 59:1925-1932.
106. Molderings G.J., Haenisch B. Agmatine (decarboxylated l-arginine): physiological role and therapeutic potential. Pharmacol. Ther. 2012, 133(3):351-365.
107. Bernstein H.-G., Stich C., Jäger K., Dobrowolny H., Wick M., Steiner J., Veh R., Bogerts B., Laube G. Agmatinase, an inactivator of the putative endogenous antidepressant agmatine, is strongly upregulated in hippocampal interneurons of subjects with mood disorders. Neuropharmacology 2012, 62:237-246.
108. Krauss M., Weiss T., Langnaese K., Richter K., Kowski A., Veh R.W., Laube G. Cellular and subcellular rat brain spermidine synthase expression patterns suggest region-specific roles for polyamines, including cerebellar pre-synaptic function. J. Neurochem. 2007, 103(2):679-693.
109. Angulo M.C., Le Meur K., Kozlov A.S., Charpak S., Audinat E. GABA, a forgotten gliotransmitter. Prog. Neurobiol. 2008, 86:297-303.
110. Laschet J., Grisar T., Bureau M., Guillaume D. Characteristics of putrescine uptake and subsequent GABA formation in primary cultured astrocytes from normal C57BL/6J and epileptic DBA/2J mouse brain cortices. Neuroscience 1992, 48(1):151-157.
111. Bernstein H.-G., Müller M. The cellular localization of the l-ornithine decarboxylase/polyamine system in normal and diseased central nervous systems. Prog. Neurobiol. 1999, 57:485-505.
112. Thompson S.G., Wong P.T.-H., Leong S.F., McGeer E.G. Regional distribution in rat brain of 1-pyrroline-5-carboxylate dehydrogenase and its localization to specific glial cells. J. Neurochem. 1985, 45:1791-1796.
113. Vincent S.R., Das S., Maines M.D. Brain heme oxygenase isoenzymes and nitric oxide synthase are co-localized in select neurons. Neuroscience 1994, 63(1):223-231.
114. Schipper H.M. Heme oxygenase-1: role in brain aging and neurodegeneration. Exp. Gerontol. 2000, 35(6-7):821-830.
115. Ryter S.W., Tyrrell R.M. The heme synthesis and degradation pathways: role in oxidant sensitivity heme oxygenase has both pro- and antioxidant properties. Free. Radic. Biol. Med. 2000, 28:289-309.
116. Ipata P.L. Origin, utilization, and recycling of nucleosides in the central nervous system. Adv. Physiol. Educ. 2011, 35:342-346.
117. Melø T.M., Nehlig A., Sonnewald U. Neuronal-glial interactions in rats fed a ketogenic diet. Neurochem. Int. 2006, 48(6-7):498-507.
118. Hasselbalch S.G., Knudsen G.M., Jakobsen J., Hageman L.P., Holm S., Paulson O.B. Brain metabolism during short-term starvation in humans. J. Cereb. Blood Flow Metab. 1994, 14:125-131.
119. Chechik T., Roeder L.M., Tildon J.T., Poduslo S.E. Ketone body enzyme activities in purified neurons, astrocytes and oligodendroglia. Neurochem. Int. 1987, 10:95-99.
120. Ellis C.E., Murphy E.J., Mitchell D.C., Golovko M.Y., Scaglia F., Barceló-Coblijn G.C., Nussbaum R.L. Mitochondrial lipid abnormality and electron transport chain impairment in mice lacking α-synuclein. Mol. Cell. Biol. 2005, 25:10190-10201.
121. Pope S., Land J.M., Heales S.J.R. Oxidative stress and mitochondrial dysfunction in neurodegeneration; cardiolipin a critical target?. Biochim. Biophys. Acta 2008, 1777(7-8):794-799.
122. Ma K., Langenbach R., Rapoport S.I., Basselin M. Altered brain lipid composition in cyclooxygenase-2 knockout mouse. J. Lipid Res. 2007, 48:848-854.
123. Pahan K., Sheikh F.G., Khan M., Namboodiri A.M., Singh I. Sphingomyelinase and ceramide stimulate the expression of inducible nitric-oxide synthase in rat primary astrocytes. J. Biol. Chem. 1998, 273:2591-2600.
124. Mitoma J., Kasama T., Furuya S., Hirabayashi Y. Occurrence of an unusual phospholipid, phosphatidyl-l-threonine, in cultured hippocampal neurons exogenous 1-serine is required for the synthesis of neuronal phosphatidyl-1-serine and sphingolipids. J. Biol. Chem. 1998, 273:19363-19366.
125. Hirabayashi Y., Furuya S. Roles of l-serine and sphingolipid synthesis in brain development and neuronal survival. Prog. Lipid Res. 2008, 47(3):188-203.
126. Yamanaka T., Hanada E., Suzuki K. Acid sphingomyelinase of human brain. Improved purification procedures and characterization. J. Biol. Chem. 1981, 256:3884-3889.
127. Lying-Tunell U., Lindblad B.S., Malmlund H.O., Persson B. Cerebral blood flow and metabolic rate of oxygen, glucose, lactate, pyruvate, ketone bodies and amino acids. Acta Neurol. Scand. 1981, 63(6):337-350.
128. Patil K.R., Nielsen J. Uncovering transcriptional regulation of metabolism by using metabolic network topology. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:2685-2689.
129. Cvijovic M., Olivares-Hernández R., Agren R., Dahr N., Vongsangnak W., Nookaew I., Patil K.R., Nielsen J. BioMet Toolbox: genome-wide analysis of metabolism. Nucleic Acids Res. 2010, 38(suppl. 2):W144-W149. 10.1093/nar/gkq404.
130. Sandelin A., Alkema W., Engström P., Wasserman W.W., Lenhard B. JASPAR: an open-access database for eukaryotic transcription factor binding profiles. Nucleic Acids Res. 2004, 32(Suppl. 1):D91-D94. 10.1093/nar/gkh012.
131. Zambelli F., Pesole G., Pavesi G. Pscan: finding over-represented transcription factor binding site motifs in sequences from co-regulated or co-expressed genes. Nucleic Acids Res. 2009, 37:W247-W252. 10.1093/nar/gkp464.
132. Lubow J.M., Piñón I.G., Avogaro A., Cobelli C., Treeson D.M., Mandeville K.A., Toffolo G., Boyle P.J. Brain oxygen utilization is unchanged by hypoglycemia in normal humans: lactate, alanine, and leucine uptake are not sufficient to offset energy deficit. Am. J. Physiol. Endocrinol. Metab. 2006, 290:E149-E153. 10.1152/ajpendo.00049.2005.
133. Madsen P.L., Cruz N.F., Sokoloff L., Dienel G.A. Cerebral oxygen/glucose ratio is low during sensory stimulation and rises above normal during recovery; excess glucose consumption during stimulation is not accounted for by lactate efflux from or accumulation in brain tissue. J. Cereb. Blood Flow Metab. 1999, 19:393-400.
134. Nybo L., Nielsen B., Blomstrand E., Møller K., Secher N. Neurohumoral responses during prolonged exercise in humans. J. Appl. Physiol. 2003, 95:1125-1131. 10.1152/japplphysiol.00241.2003.
135. Wahren J., Ekberg K., Fernqvist-Forbes E., Nair S. Brain substrate utilisation during acute hypoglycemia. Diabetologia 1999, 42:812-818.
136. Gruetter R., Seaquist E.R., Ugurbil K. A mathematical model of compartmentalized neurotransmitter metabolism in the human brain. Am. J. Physiol. Endocrinol. Metab. 2001, 281:E100-E112.
137. Lebon V., Petersen K.F., Cline G.W., Shen J., Mason G.F., Dufour S., Behar K.L., Shulman G.I., Rothman D.L. Astroglial contribution to brain energy metabolism in humans revealed by 13C nuclear magnetic resonance spectroscopy: elucidation of the dominant pathway for neurotransmitter glutamate repletion and measurement of astrocytic oxidative metabolism. J. Neurosci. 2002, 22:1523-1531.
138. 2 fixation increases with brain activity. J. Neurosci. 2004, 24:11273-11279.
139. Hertz L., Peng L., Dienel G.A. Energy metabolism in astrocytes: high rate of oxidative metabolism and spatiotemporal dependence on glycolysis/glycogenolysis. J. Cereb. Blood Flow Metab. 2006, 27:219-249.
140. Siegel G.J., Agranoff B.W., Albers R.W., Molinoff P.B. Basic Neurochemistry: Molecular, Cellular, and Medical Aspects 1994, Raven Press.
141. Wiesinger H., Hamprecht B., Dringen R. Metabolic pathways for glucose in astrocytes. Glia 1997, 21:22-34.
142. Ben-Yoseph O., Camp D.M., Robinson T.E., Ross B.D. Dynamic measurements of cerebral pentose phosphate pathway activity in vivo using [1, 6-13C2, 6, 6-2H2] glucose and microdialysis. J. Neurochem. 1995, 64:1336-1342.
143. 13C NMR spectroscopy. Brain Res. 1997, 765:218-227.